[go: up one dir, main page]

PE20120010A1 - Cefalosporinas que tienen un grupo catecol - Google Patents

Cefalosporinas que tienen un grupo catecol

Info

Publication number
PE20120010A1
PE20120010A1 PE2011000941A PE2011000941A PE20120010A1 PE 20120010 A1 PE20120010 A1 PE 20120010A1 PE 2011000941 A PE2011000941 A PE 2011000941A PE 2011000941 A PE2011000941 A PE 2011000941A PE 20120010 A1 PE20120010 A1 PE 20120010A1
Authority
PE
Peru
Prior art keywords
lower alkylene
single link
link
substituted
catecol
Prior art date
Application number
PE2011000941A
Other languages
English (en)
Inventor
Yasuhiro Nishitani
Kenji Yamawaki
Hideki Sugimoto
Shinya Hisakawa
Aoki Toshiaki
Yusuke Takeoka
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42128829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120010(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of PE20120010A1 publication Critical patent/PE20120010A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO DE FORMULA I, DONDE X ES N, CH, C-Cl; T ES S, S=O, CH2, O; A ES ALQUILENO INFERIOR, ALQUENILENO INFERIOR, ENTRE OTROS; G ES ENLACE SENCILLO, ALQUILENO INFERIOR SUSTITUIDO O NO, ALQUENILENO INFERIOR SUSTITUIDO O NO, ENTRE OTROS; B ES UN ENLACE SENCILLO, HETEROCICLO DE 5-6 MIEMBROS CON 1-3 ATOMOS DE N; D ES ENLACE SENCILLO, CO, O-CO, CO-O; E ES ALQUILENO INFERIOR SUSTITUIDO O NO; F ES ENLACE SENCILLO, FENILENO SUSTITUIDO O NO; R3, R4, R5, Y R6 SON CADA UNOH, HALOGENO, NITRILO, ENTRE OTROS; EL CICLO DE FORMULA II ES UN AMONIO CUATERNARIO, CICLICO, MONOCICLICO O FUSIONADO, SATURADO O INSATURADO; LA LINEA DE PUNTOS MUESTRA UN ENLACE. UN COMPUESTO PREFERIDO ES: I-2. DICHOS COMPUESTOS TIENEN AMPLIO ESPECTRO ANTIMICROBIANO
PE2011000941A 2008-10-31 2009-10-27 Cefalosporinas que tienen un grupo catecol PE20120010A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008280828 2008-10-31

Publications (1)

Publication Number Publication Date
PE20120010A1 true PE20120010A1 (es) 2012-02-07

Family

ID=42128829

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011000941A PE20120010A1 (es) 2008-10-31 2009-10-27 Cefalosporinas que tienen un grupo catecol

Country Status (38)

Country Link
US (1) US9238657B2 (es)
EP (2) EP2341053B1 (es)
JP (2) JP5498393B2 (es)
KR (1) KR101655961B1 (es)
CN (1) CN102203100B (es)
AU (1) AU2009310959B2 (es)
BR (1) BRPI0921701B8 (es)
CA (1) CA2736953C (es)
CL (1) CL2011000939A1 (es)
CO (1) CO6331443A2 (es)
CR (1) CR20110144A (es)
CY (2) CY1118536T1 (es)
DK (1) DK2960244T3 (es)
EA (1) EA019520B1 (es)
ES (2) ES2564836T3 (es)
FI (1) FIC20200039I1 (es)
FR (1) FR20C1050I2 (es)
HR (1) HRP20161408T1 (es)
HU (2) HUE031802T2 (es)
IL (1) IL211720A (es)
LT (2) LT2960244T (es)
MA (1) MA32731B1 (es)
ME (1) ME02666B (es)
MX (1) MX2011004636A (es)
MY (1) MY155655A (es)
NL (1) NL301067I2 (es)
NO (1) NO2020035I1 (es)
NZ (1) NZ591728A (es)
PE (1) PE20120010A1 (es)
PL (1) PL2960244T3 (es)
PT (1) PT2960244T (es)
RS (1) RS55365B1 (es)
SI (1) SI2960244T1 (es)
SM (1) SMT201600397B (es)
TW (1) TWI535727B (es)
UA (1) UA105190C2 (es)
WO (1) WO2010050468A1 (es)
ZA (1) ZA201102024B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2935651A1 (en) 2007-10-09 2009-04-16 Gladius Pharmaceuticals Corporation Broad spectrum beta-lactamase inhibitors
MX2011004636A (es) 2008-10-31 2011-06-20 Shionogi & Co Cefarosporinas que tienen un grupo catecol.
WO2011125966A1 (ja) * 2010-04-05 2011-10-13 塩野義製薬株式会社 擬似カテコール基を有するセフェム化合物
CA2795322A1 (en) 2010-04-05 2011-10-13 Shionogi & Co., Ltd. Cephem compound having catechol group
JP5852562B2 (ja) * 2010-04-28 2016-02-03 塩野義製薬株式会社 新規なセフェム誘導体
EP2966061B1 (en) * 2011-03-04 2017-05-03 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
KR101719556B1 (ko) * 2011-03-30 2017-03-24 주식회사 레고켐 바이오사이언스 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물
WO2012147773A1 (ja) 2011-04-28 2012-11-01 塩野義製薬株式会社 カテコールまたは擬似カテコール構造を有する新規セフェム化合物
WO2013002215A1 (ja) 2011-06-27 2013-01-03 塩野義製薬株式会社 ピリジニウム基を有するセフェム化合物
US9290515B2 (en) 2011-10-04 2016-03-22 Shionogi & Co., Ltd Cephem derivative having catechol group
TWI547496B (zh) * 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
AU2013339040A1 (en) 2012-10-29 2015-04-30 Shionogi & Co., Ltd. Processes for production of intermediates for 2-alkyl cephem compounds
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
JPWO2014104148A1 (ja) * 2012-12-26 2017-01-12 塩野義製薬株式会社 セフェム化合物
AU2014233637A1 (en) 2013-09-09 2015-03-26 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
KR101733441B1 (ko) 2014-03-24 2017-05-10 노파르티스 아게 박테리아 감염의 치료를 위한 모노박탐 유기 화합물
JP6377570B2 (ja) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２−置換セフェム化合物を含有する医薬組成物
EP3882252B1 (en) 2014-06-11 2025-11-19 Venatorx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN106661052B (zh) * 2014-09-04 2021-05-11 盐野义制药株式会社 头孢菌素衍生物的中间体及其制造方法
WO2016035846A1 (ja) * 2014-09-04 2016-03-10 塩野義製薬株式会社 カテコール基を有するセファロスポリン類を含有する製剤
US10004750B2 (en) * 2014-09-04 2018-06-26 Shionogi & Co., Ltd. Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
WO2016198691A1 (en) 2015-06-11 2016-12-15 Basilea Pharmaceutica Ag Efflux-pump inhibitors and therapeutic uses thereof
JP6837480B2 (ja) 2015-09-23 2021-03-03 ノバルティス アーゲー モノバクタム抗生物質の塩および固体形態
HK1254209A1 (zh) * 2015-12-10 2019-07-12 Naeja-Rgm Pharmaceuticals Ulc 头孢烯化合物、其制备和用途
WO2017153919A1 (en) 2016-03-08 2017-09-14 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
EP3471724A1 (en) * 2016-06-17 2019-04-24 Wockhardt Limited Antibacterial compositions
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
EP3634471A4 (en) * 2017-06-09 2021-02-24 FOB Synthesis, Inc. Carbapenem compounds and compositions for the treatment of bacterial infections
CN111094281B (zh) * 2017-08-02 2023-08-29 诺华股份有限公司 用于制备单内酰胺抗生素的化学方法及其中间体
FI3759113T3 (fi) 2018-02-28 2024-11-01 Novartis Ag 10-(di(fenyyli)metyyli)-4-hydroksi-8,9,9a,10-tetrahydro-7h-pyrrolo[1’,2’:4,5]pyratsino[1,2-b]pyridatsiini-3,5-dionijohdannaisia ja niihin liittyviä yhdisteitä ortomyksoviruksen replikaation estäjinä influenssan hoidossa
WO2019226931A1 (en) 2018-05-25 2019-11-28 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020184399A1 (ja) * 2019-03-08 2020-09-17 塩野義製薬株式会社 抗菌用医薬組成物
BR112022004107A2 (pt) 2019-09-06 2022-05-31 Nabriva Therapeutics GmbH Conjugados de cefalosporina de sideróforo e seus usos
BR112022014321A2 (pt) * 2020-01-22 2022-09-13 Shanghai Senhui Medicine Co Ltd Composto antibacteriano de cefalosporina e aplicação farmacêutica do mesmo
TW202220663A (zh) 2020-07-28 2022-06-01 日商鹽野義製藥股份有限公司 含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法
JP2024503656A (ja) * 2021-01-12 2024-01-26 上海森▲輝▼医▲葯▼有限公司 セファロスポリン系抗菌化合物及びその調製方法
CN113698365A (zh) * 2021-08-30 2021-11-26 成都大学 一种头孢地尔侧链的制备方法
WO2024245383A1 (zh) 2023-06-01 2024-12-05 江苏恒瑞医药股份有限公司 一种包含头孢类抗菌化合物的药物组合物
CN117024377B (zh) * 2023-08-15 2025-04-29 济南大学 一种2-氯-3,4-二对甲氧苯甲氧基-n-(2-(1-吡咯烷)乙基)苯甲酰胺的制备方法
CN117069638A (zh) * 2023-08-17 2023-11-17 济南大学 一种头孢地尔中间体的制备方法
US12225906B1 (en) 2024-09-26 2025-02-18 Terry Earl Brady Pathogenic affinity pathway of infectious or parasitic organisms for nanogram and picogram dosimetry prophylaxis or cure

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
JPS57118588A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel cephalosporin
DE3207840A1 (de) 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
EP0114752B1 (en) 1983-01-21 1988-04-06 Beecham Group Plc Beta-lactam antibacterial agents
NO165842C (no) 1984-04-23 1991-04-17 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
EP0168177A3 (en) 1984-06-28 1987-04-01 Pfizer Limited Cephalosporin antibiotics
NO166283C (no) 1985-03-01 1991-06-26 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive 7beta-(2-(5-amino-1,2,4-tiadiazol-3-yl)-2(z)-substituertoksyiminoacetamido)-3-(heterocyclylmetyl)-3-cefem-4-karboksylsyrederivater.
JPH068300B2 (ja) * 1985-08-02 1994-02-02 萬有製薬株式会社 新規セフアロスポリン誘導体
EP0211656A3 (en) 1985-08-10 1988-03-09 Beecham Group Plc Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
JPH07107069B2 (ja) * 1985-09-03 1995-11-15 大塚化学株式会社 セフアロスポリン化合物の新規誘導体、その製造法及び該誘導体を含有する医薬組成物
ATE82976T1 (de) * 1985-09-03 1992-12-15 Otsuka Kagaku Kk Cephalosporinderivate.
JPS62158291A (ja) * 1986-01-07 1987-07-14 Sagami Chem Res Center セフアロスポリン誘導体
WO1987006232A1 (fr) * 1986-04-14 1987-10-22 Banyu Pharmaceutical Co., Ltd. Derives de 1-carboxy-1-vinyloxyiminoaminothiazole cephalosporine et leur procede de preparation
ATE110386T1 (de) * 1986-04-14 1994-09-15 Banyu Pharma Co Ltd Cephalosporinderivate, verfahren zu ihrer herstellung und antibakterielle präparate.
IE61679B1 (en) 1987-08-10 1994-11-16 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
GB8719875D0 (en) 1987-08-22 1987-09-30 Beecham Group Plc Compounds
JPH0228185A (ja) 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
US5149803A (en) * 1988-05-10 1992-09-22 Imperial Chemical Industries Plc Intermediates for cephalosporin compounds
GB8811055D0 (en) 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
US5244890A (en) 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
PH25965A (en) 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
GB8813945D0 (en) 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) * 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
JPH02275886A (ja) 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
CA2005787A1 (en) 1988-12-29 1990-06-29 Masao Wada Cephalosporin compounds
US5143910A (en) 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5126336A (en) * 1990-08-23 1992-06-30 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
US5234920A (en) 1990-08-23 1993-08-10 Bristol-Myers Squibb Company Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5095012A (en) 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5194433A (en) * 1990-11-13 1993-03-16 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
EP0628562A1 (fr) 1993-06-10 1994-12-14 Roussel Uclaf Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments
WO1999033839A1 (en) 1997-12-26 1999-07-08 Cheil Jedang Corporation Cephem derivatives and a method for producing the compounds and an antibacterial composition containing the compounds
WO2002076979A1 (en) 2001-03-27 2002-10-03 Actelion Pharmaceuticals Ltd 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
JP2003078440A (ja) 2001-08-30 2003-03-14 Kyocera Corp 高周波スイッチ回路
TW200305422A (en) * 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
WO2003099826A1 (en) 2002-05-23 2003-12-04 Orchid Chemicals And Pharmaceuticals Limited A new process for the preparation of cefditoren using the thioester of thiazolylacetic acid
JP4892926B2 (ja) 2005-10-25 2012-03-07 宇部興産株式会社 スルホン化芳香族ブロック共重合体の製造方法
WO2006104141A1 (ja) 2005-03-29 2006-10-05 Shionogi & Co., Ltd. ３－プロペニルセフェム誘導体
JP4557859B2 (ja) 2005-09-29 2010-10-06 富士通株式会社 周波数分割多重送受信装置及び送受信方法
WO2007096740A2 (en) 2006-02-20 2007-08-30 Orchid Research Laboratories Limited Novel cephalosporins
WO2007119511A1 (en) * 2006-03-16 2007-10-25 Astellas Pharma Inc. Cephem compounds and use as antimicrobial agents
MX2011004636A (es) 2008-10-31 2011-06-20 Shionogi & Co Cefarosporinas que tienen un grupo catecol.
WO2011125966A1 (ja) 2010-04-05 2011-10-13 塩野義製薬株式会社 擬似カテコール基を有するセフェム化合物
CA2795322A1 (en) 2010-04-05 2011-10-13 Shionogi & Co., Ltd. Cephem compound having catechol group
JP5852562B2 (ja) 2010-04-28 2016-02-03 塩野義製薬株式会社 新規なセフェム誘導体

Also Published As

Publication number Publication date
ME02666B (me) 2017-06-20
PT2960244T (pt) 2016-11-02
CO6331443A2 (es) 2011-10-20
CA2736953C (en) 2017-07-11
DK2960244T3 (en) 2016-11-28
IL211720A0 (en) 2011-06-30
SI2960244T1 (sl) 2017-02-28
HUS2000042I1 (hu) 2020-11-30
EP2341053B1 (en) 2016-01-13
US20110190254A1 (en) 2011-08-04
UA105190C2 (ru) 2014-04-25
BRPI0921701B1 (pt) 2022-05-03
JP2014065732A (ja) 2014-04-17
MX2011004636A (es) 2011-06-20
EP2341053A4 (en) 2012-08-08
CR20110144A (es) 2011-09-09
AU2009310959A1 (en) 2010-05-06
LTPA2020530I1 (lt) 2020-11-10
CY2020034I2 (el) 2021-05-05
TW201020259A (en) 2010-06-01
CY1118536T1 (el) 2017-07-12
US9238657B2 (en) 2016-01-19
FIC20200039I1 (fi) 2020-10-19
JPWO2010050468A1 (ja) 2012-03-29
EP2960244B1 (en) 2016-09-14
ZA201102024B (en) 2014-08-27
IL211720A (en) 2015-01-29
RS55365B1 (sr) 2017-03-31
CN102203100A (zh) 2011-09-28
HUE031802T2 (en) 2017-08-28
JP5498393B2 (ja) 2014-05-21
EP2960244A1 (en) 2015-12-30
HRP20161408T1 (hr) 2016-12-02
LTC2960244I2 (lt) 2023-10-10
NL301067I2 (nl) 2020-10-28
EA019520B1 (ru) 2014-04-30
TWI535727B (zh) 2016-06-01
SMT201600397B (it) 2017-01-10
BRPI0921701B8 (pt) 2022-11-29
CN102203100B (zh) 2014-08-27
LT2960244T (lt) 2016-11-25
MY155655A (en) 2015-11-13
KR101655961B1 (ko) 2016-09-08
PL2960244T3 (pl) 2017-03-31
NZ591728A (en) 2012-12-21
KR20110090982A (ko) 2011-08-10
MA32731B1 (fr) 2011-10-02
CA2736953A1 (en) 2010-05-06
ES2564836T3 (es) 2016-03-29
EA201170632A1 (ru) 2011-12-30
NO2020035I1 (no) 2020-10-21
ES2602969T3 (es) 2017-02-23
CL2011000939A1 (es) 2011-09-16
WO2010050468A1 (ja) 2010-05-06
CY2020034I1 (el) 2020-11-25
BRPI0921701A2 (pt) 2020-08-11
FR20C1050I1 (es) 2020-11-27
EP2341053A1 (en) 2011-07-06
AU2009310959B2 (en) 2015-05-07
NL301067I1 (es) 2020-10-13
FR20C1050I2 (fr) 2021-10-15

Similar Documents

Publication Publication Date Title
PE20120010A1 (es) Cefalosporinas que tienen un grupo catecol
CR10057A (es) Compuesto heterocíclico fusionado
CO6321166A2 (es) Compuestos de pirrol
PA8649401A1 (es) Analogos de anilino-pirimidina
GT200400173A (es) Compuestos de aril o heteroaril amida
EA202091477A1 (ru) Замещенные соединения простых индольных эфиров
AR057914A1 (es) Compuestos organicos de azufre y su uso
EA201070246A1 (ru) Циклические аминные соединения
CY1112914T1 (el) Υποκατεστημενα παραγωγα ινδολυλ αλκυλ αμινης ως νεοι αναστολεις των αποακετυλασων ιστονης
PA8610601A1 (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4
EP1889835A4 (en) CYCLIC AMINE DERIVATIVE WITH SUBSTITUTED ALKYL GROUP
BRPI0508966A (pt) composto, composição farmacêutica, e, uso de um composto
EA201591277A1 (ru) Пирролобензодиазепины и их конъюгаты
BR112015002017A2 (pt) composto do tipo amida
BR112015016580A2 (pt) composto heterocíclico contendo nitrogênio ou sal deste
CY1114836T1 (el) Παραγωγο δικυκλικου γ-αμινοξεος
ES2620379T3 (es) Quinolina y quinoxalina amidas como moduladores de canales de sodio
TW200730490A (en) Photoactive compounds
CY1113485T1 (el) Ενωσεις γεφυρωμενης-πιπεριδινης τυπου υποκατεστημενης-κινοξαλινης και οι χρησεις εξ' αυτων
AR027293A1 (es) Derivados aminados de dihidro-1,3,5-triazina y sus aplicaciones en terapeutica
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
MA32956B1 (fr) Derives de 5-amino-2-(1-hydroxyethyl)-tetrahydropyrane
PE20170184A1 (es) Derivados de piperidina como antagonista de receptores de orexina
PH12017500630B1 (en) Fabric enhancer composition
BR112014032563A2 (pt) composto de amida e uso do mesmo para controle de peste

Legal Events

Date Code Title Description
FG Grant, registration